Study of two drugs with chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic colorectal cancer that has spread to other parts of the body.
- You have not had any chemotherapy or other treatment for your cancer that has spread.
- You should be in fairly good health, able to care for yourself and up and about more than half of the day.
- You do not have certain genetic subtypes of colorectal cancer (MSI-H, dMMR, or BRAF V600E mutation).
- You do not currently have a bowel blockage or significant fluid in the belly that needed draining in the last month.
- You do not have a history of inflammatory bowel disease (like Crohn's or ulcerative colitis) or ongoing chronic diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for advanced colorectal cancer. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial compares two combinations of drugs for people with a certain type of advanced colorectal cancer that has progressed after initial treatment. It aims to see if one combination works better than the other, potentially offering a new option for second-line therapy.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.